Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Research & Development (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Research & Development for 7 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 62.38% to $3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.6 million, a 13.59% decrease, with the full-year FY2025 number at $27.2 million, down 34.92% from a year prior.
  • Research & Development was $3.6 million for Q4 2025 at Outlook Therapeutics, down from $8.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $9.7 million in Q4 2024 to a low of $3.6 million in Q4 2025.